Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A3 | Q16572 | 2/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | NGLY1 | Q96IV0 | 1/20 | 0.33 |
| ▸ | GBA2 | Q9HCG7 | 1/20 | 0.33 |
| ▸ | GBA1 | P04062 | 1/20 | 0.33 |
| ▸ | GANAB | Q14697 | 1/20 | 0.33 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3391750 | 1.00 | SLC18A3 (0.38) | SLC18A3PKMGAAMEN1CYP1A2 | |
| SCHEMBL7293477 | 0.83 | GAA (0.34) | SLC18A3GAAMEN1CYP1A2CYP2C9 | |
| SCHEMBL24705597 | 0.77 | — | — | |
| SCHEMBL11295539 | 0.77 | — | — | |
| SCHEMBL5398154 | 0.72 | SLC18A3 (0.41) | SLC18A3PKMGAAMEN1CYP1A2 | |
| SCHEMBL27816064 | 0.72 | SLC18A3 (0.41) | SLC18A3PKMGAAMEN1CYP1A2 | |
| SCHEMBL1404038 | 0.70 | SLC18A3 (0.44) | SLC18A3PKMGAAMEN1CYP1A2 | |
| Bicarbonate SCHEMBL28128479 | 0.69 | KDM4E (0.36) | SLC18A3MEN1KMT2A | |
| SCHEMBL7281278 | 0.68 | CHRNA7 (0.33) | CHRNA7 | |
| SCHEMBL6519582 | 0.68 | SLC18A3 (0.38) | SLC18A3PKMGAAMEN1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3444252-B1 | ELECTROCHEMICAL CELL COMPRISING A HETERO IONIC ADDITIVE | NANTENERGY INC (US) | 2019-08-14 | — | — | EP | claimed |
| EP-3444252-A1 | SYNTHESIS OF HETERO IONIC COMPOUNDS USING DIALKYLCARBONATE QUATERNIZATION | NantEnergy, Inc. (US) | 2019-02-20 | — | — | EP | claimed |
| EP-3336962-B1 | ELECTROCHEMICAL CELL COMPRISING ELECTROLYTE HAVING HETERO IONIC COMPLEX | NANTENERGY INC (US) | 2019-02-20 | — | — | EP | claimed |
| EP-3336962-A1 | ELECTROCHEMICAL CELL COMPRISING ELECTROLYTE HAVING HETERO IONIC COMPLEX | Fluidic, Inc. (US) | 2018-06-20 | — | — | EP | claimed |
| US-9793586-B2 | Synthesis of hetero compounds using dialkylcarbonate quaternation | FLUIDIC, INC. (US) | 2017-10-17 | — | — | US | claimed |
| US-9768472-B2 | Synthesis of hetero ionic compounds using dialkylcarbonate quaternization | FLUIDIC, INC. (US) | 2017-09-19 | — | — | US | claimed |
| US-20170233877-A9 | SYNTHESIS OF HETERO COMPOUNDS USING DIALKYLCARBONATE QUATERNATION | FLUIDIC, INC. (US) | 2017-08-17 | — | — | US | claimed |
| US-20170092989-A1 | SYNTHESIS OF HETERO IONIC COMPOUNDS USING DIALKYLCARBONATE QUATERNIZATION | FLUIDIC, INC. | 2017-03-30 | — | — | US | claimed |
| EP-2721037-A1 | SYNTHESIS OF HETERO IONIC COMPOUNDS USING DIALKYLCARBONATE QUATERNIZATION | Fluidic, Inc. (US) | 2014-04-23 | — | — | EP | claimed |
| US-20120321969-A1 | SYNTHESIS OF HETERO COMPOUNDS USING DIALKYLCARBONATE QUATERNATION | FLUIDIC, INC. (US) | 2012-12-20 | — | — | US | claimed |
| WO-2012174564-A1 | SYNTHESIS OF HETERO IONIC COMPOUNDS USING DIALKYLCARBONATE QUATERNIZATION | FLUIDIC, INC. (US) | 2012-12-20 | — | — | WO | claimed |
| EP-2457911-A1 | 3-(heteroaryl-oxy)-2-alkyl-1-aza-bicycloalkyl derivatives as alpha.7-nAChR ligands for the treatment of CNS diseases. | Novartis AG (CH) | 2012-05-30 | — | — | EP | claimed |
| US-20080194573-A1 | Psychological and neurodegenerative disorders; nicotinic acetylcholine receptors | NOVARTIS AG (CH) | 2008-08-14 | — | — | US | claimed |
| EP-1776360-A1 | 3-(HETEROARYL-OXY)-2-ALKYL-1-AZA-BICYCLOALKYL DERIVATIVES AS ALPHA.7-NACHR LIGANDS FOR THE TREATMENT OF CNS DISEASES. | Novartis AG (CH) | 2007-04-25 | — | — | EP | claimed |
| WO-2006005608-A1 | 3-(HETEROARYL-OXY)-2-ALKYL-1-AZA-BICYCLOALKYL DERIVATIVES AS ALPHA.7-NACHR LIGANDS FOR THE TREATMENT OF CNS DISEASES | NOVARTIS AG (CH) | 2006-01-19 | — | — | WO | claimed |
| EP-4559918-A2 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | Genzyme Corporation (US) | 2025-05-28 | — | — | EP | disclosed |
| EP-3673906-B1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GENZYME CORP (US) | 2025-05-14 | — | — | EP | disclosed |
| US-6124354-A | TREATMENT OF URINARY INCONTINENCE OR IRRITABLE BOWEL SYNDROME | PHARMACIA & UPJOHN AB (SE) | 2000-09-26 | — | — | US | disclosed |
| EP-0923536-A1 | ARYLCYCLOALKANE CARBOXYLIC ESTERS, THEIR USE, PHARMACEUTICAL COMPOSITIONS AND PREPARATION | Pharmacia & Upjohn Aktiebolag (SE) | 1999-06-23 | — | — | EP | disclosed |
| WO-1998004517-A1 | ARYLCYCLOALKANE CARBOXYLIC ESTERS, THEIR USE, PHARMACEUTICAL COMPOSITIONS AND PREPARATION | PHARMACIA & UPJOHN AB (SE) | 1998-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194573-A1 | Psychological and neurodegenerative disorders; nicotinic acetylcholine receptors | CHRNA7, CHRNA5, CHRNA6 | SLC18A3 33/4885PKM 4168/4885GAA 1025/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.